<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">L Van Baelen</style></author><author><style face="normal" font="default" size="100%">Johan Van der Heyden</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hepatitis C virus prevalence in Belgium</style></title><secondary-title><style face="normal" font="default" size="100%">Experimental Results</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">cross-sectional study</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis C</style></keyword><keyword><style  face="normal" font="default" size="100%">population estimate</style></keyword><keyword><style  face="normal" font="default" size="100%">Seroprevalence</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">2</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Reliable hepatitis C prevalence estimates are crucial for a good follow-up of the indicators to eliminate hepatitis by 2030 as set by the World Health Organization. In Belgium, no recent national population-based hepatitis C virus (HCV) seroprevalence estimate is available. The current study estimated HCV prevalence as part of the first Belgian Health Examination Survey, which was organized in 2018 as a second stage of the sixth Belgian Health Interview Survey. This national population-based cross-sectional study resulted in a weighted national HCV seroprevalence of 0.02% (95% CI 0.00–0.07%). The results show a much lower HCV seroprevalence compared to previous studies.&lt;/p&gt;
</style></abstract></record></records></xml>